Bioventix (LON:BVXP – Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported GBX 145.74 EPS for the quarter, Digital Look Earnings reports. Bioventix had a net margin of 59.30% and a return on equity of 65.83%. The firm had revenue of GBX 1,297 million for the quarter.
Bioventix Stock Performance
Shares of Bioventix stock opened at GBX 2,013 on Tuesday. The stock has a 50 day moving average of GBX 1,694.82 and a 200 day moving average of GBX 1,656.41. The firm has a market capitalization of £105.18 million, a price-to-earnings ratio of 14.33 and a beta of 0.54. Bioventix has a fifty-two week low of GBX 1,300 and a fifty-two week high of GBX 2,255.
Bioventix Company Profile
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Read More
- Five stocks we like better than Bioventix
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
Receive News & Ratings for Bioventix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix and related companies with MarketBeat.com's FREE daily email newsletter.
